Muscle Spasticity - Pipeline Review, H2 2019

December 2019 | 110 pages | ID: MDA19B7A44E2EN
Global Markets Direct

Abstracts

Muscle Spasticity - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Spasticity - Pipeline Review, H2 2019, provides an overview of the Muscle Spasticity (Central Nervous System) pipeline landscape.

Spasticity is a condition in which certain muscles are continuously contracted. Symptoms include muscle tightness, joint stiffness, involuntary jerky movements, exaggeration of reflexes, unusual posture, abnormal positioning of fingers, wrists, arms, or shoulders and muscle spasms. Treatment includes relieving the signs and symptoms of spasticity and reducing the pain and frequency of muscle contractions.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscle Spasticity - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Muscle Spasticity (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscle Spasticity (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Muscle Spasticity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 4, 5, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Muscle Spasticity (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Muscle Spasticity (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Muscle Spasticity (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Muscle Spasticity (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Muscle Spasticity (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Spasticity (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Muscle Spasticity (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Muscle Spasticity (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Muscle Spasticity - Overview
Muscle Spasticity - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Muscle Spasticity - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscle Spasticity - Companies Involved in Therapeutics Development
Allaysis LLC
Axim Biotechnologies Inc
CytoDel Inc
Ethicann Pharmaceuticals Inc
Genochem SAS
GW Pharmaceuticals Plc
H. Lundbeck AS
Harvest One Cannabis Inc
Ipsen SA
Medytox Inc
Merz Pharma GmbH & Co KgaA
OBI Pharma Inc
Osmotica Pharmaceutical Corp
Revance Therapeutics Inc
Sanochemia Pharmazeutika AG
Sun Pharma Advanced Research Company Ltd
Vitality Biopharma Inc
Muscle Spasticity - Drug Profiles
Muscle Spasticity - Dormant Projects
Muscle Spasticity - Discontinued Products
Muscle Spasticity - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Muscle Spasticity, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Muscle Spasticity - Pipeline by Allaysis LLC, H2 2019
Muscle Spasticity - Dormant Projects, H2 2019
Muscle Spasticity - Dormant Projects, H2 2019 (Contd..1), H2 2019
Muscle Spasticity - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Muscle Spasticity, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019